Cybin Appoints Co-Founder Eric So as Interim CEO Following Drysdale's Departure
TL;DR
Cybin's CEO transition positions interim leader Eric So to accelerate clinical pipeline development, potentially gaining competitive advantage in neuropsychiatry treatments.
Cybin's structured leadership change involves a board committee search for a new CEO while So focuses on advancing Phase 3 CYB003 and Phase 2 CYB004 trials.
Cybin's leadership continuity ensures continued development of novel mental health treatments that could revolutionize care for millions suffering from depression and anxiety.
Cybin develops deuterated psychedelic analogs like CYB003 for depression, showing how ancient compounds are being reinvented for modern mental health treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc. announced the appointment of co-founder and president Eric So as interim chief executive officer effective September 2, 2025, following the departure of Doug Drysdale from the CEO role. The company's board of directors has established a committee to conduct a search for a permanent CEO to lead Cybin through its commercialization phase.
During this transition period, So will focus on advancing the company's clinical pipeline, which includes CYB003 and CYB004, while ensuring operational continuity. CYB003, Cybin's proprietary deuterated psilocin analog, is currently in Phase 3 studies for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
The leadership change comes at a critical juncture for Cybin, a late-stage neuropsychiatry company committed to developing innovative treatment options for mental health conditions. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 studies for generalized anxiety disorder, along with a research pipeline of investigational 5-HT-receptor focused compounds.
This executive transition is significant for investors and the mental health treatment landscape, as leadership stability is crucial for companies navigating late-stage clinical development and approaching commercialization. The appointment of a co-founder as interim CEO suggests the board values internal expertise and continuity during this period of transition.
The company maintains operations across Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to addressing the substantial unmet need in mental healthcare. Investors can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.
For the investment community, executive changes at publicly traded companies like Cybin often signal strategic shifts or preparation for new phases of growth. The formation of a CEO search committee indicates the board is taking a deliberate approach to selecting leadership capable of guiding the company through commercialization of its novel psychiatric treatments.
Curated from InvestorBrandNetwork (IBN)
